Keywords: Pharmaxis, Bronchitol, Cystic fibrosis, USA, FDA, Complete response letter

US FDA calls for new trial with Pharmaxis' CF drug Bronchitol

Article | 19 March 2013

Print This

Australian pharma company Pharmaxis (ASX: PXS) says it has received a complete response letter from the Food and Drug Administration ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in